## Anne Caignard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2357867/publications.pdf

Version: 2024-02-01

100 papers 5,771 citations

94433 37 h-index 76900 74 g-index

102 all docs

102 docs citations

102 times ranked 7396 citing authors

#	Article	IF	CITATIONS
1	Innate lymphoid cells: NK and cytotoxic ILC3 subsets infiltrate metastatic breast cancer lymph nodes. Oncolmmunology, 2022, $11$ , 2057396.	4.6	9
2	Challenges for NK cell-based therapies: What can we learn from lymph nodes?., 2021,, 33-51.		0
3	Specific Patterns of Blood ILCs in Metastatic Melanoma Patients and Their Modulations in Response to Immunotherapy. Cancers, 2021, 13, 1446.	3.7	12
4	BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis., 2020, 8, e000275.		11
5	Two-dimensional dynamic evaluation of natural killer cell-mediated lysis of adherent target cells. Methods in Enzymology, 2020, 631, 289-304.	1.0	O
6	NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment. Frontiers in Immunology, 2019, 10, 661.	4.8	65
7	T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants. Annals of Oncology, 2019, 30, 934-944.	1.2	20
8	Circulating NKp46 <sup>+</sup> Natural Killer cells have a potential regulatory property and predict distinct survival in Non-Small Cell Lung Cancer. Oncolmmunology, 2019, 8, e1527498.	4.6	28
9	CD16+NKG2Ahigh Natural Killer Cells Infiltrate Breast Cancer–Draining Lymph Nodes. Cancer Immunology Research, 2019, 7, 208-218.	3.4	32
10	TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer. Oncolmmunology, 2018, 7, e1386826.	4.6	26
11	NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients. Oncolmmunology, 2017, 6, e1137418.	4.6	42
12	Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer. Oncolmmunology, 2017, 6, e1163456.	4.6	30
13	Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on <i>BRAF</i> V600E Melanoma Lines with Vemurafenib. Cancer Immunology Research, 2017, 5, 582-593.	3.4	17
14	Immune Modifications in Fetal Membranes Overlying the Cervix Precede Parturition in Humans. Journal of Immunology, 2017, 198, 1345-1356.	0.8	39
15	Tumor-Derived Mesenchymal Stem Cells Use Distinct Mechanisms to Block the Activity of Natural Killer Cell Subsets. Cell Reports, 2017, 20, 2891-2905.	6.4	86
16	Patient's Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers. Frontiers in Immunology, 2017, 8, 683.	4.8	10
17	Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells. Frontiers in Immunology, 2016, 7, 94.	4.8	26
18	Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15. Frontiers in Immunology, 2016, 7, 413.	4.8	77

#	Article	IF	CITATIONS
19	NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: Unique NKp30 pattern in rare melanoma patients with favorable evolution. Oncolmmunology, 2016, 5, e1154251.	4.6	20
20	Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy. International Immunopharmacology, 2016, 40, 466-473.	3.8	25
21	Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response. Oncolmmunology, 2016, 5, 1136045.	4.6	22
22	Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. Journal of Clinical Investigation, 2016, 126, 921-937.	8.2	71
23	Characterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients. PLoS ONE, 2015, 10, e0133363.	2,5	14
24	Consensus nomenclature for CD8 <sup>+</sup> T cell phenotypes in cancer. Oncolmmunology, 2015, 4, e998538.	4.6	119
25	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	1.8	395
26	When unity makes strength. Oncolmmunology, 2014, 3, e28048.	4.6	3
27	Mature Cytotoxic CD56bright/CD16 <i>+</i> Natural Killer Cells Can Infiltrate Lymph Nodes Adjacent to Metastatic Melanoma. Cancer Research, 2014, 74, 81-92.	0.9	85
28	Regulation of CD4+NKG2D+ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15Rα and NKG2D Triggering. Cancer Research, 2014, 74, 68-80.	0.9	43
29	Obesity and renal cancer. Oncolmmunology, 2014, 3, e27810.	4.6	55
30	High number of CD56bright NK-cells and persistently low CD4+ T-cells in a hemophiliac HIV/HCV co-infected patient without opportunistic infections. Virology Journal, 2013, 10, 33.	3.4	7
31	Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors. Cancer Research, 2013, 73, 3499-3510.	0.9	277
32	Expression of IL-27 by Tumor Cells in InvasCutaneous and Metastatic Melanomas. PLoS ONE, 2013, 8, e75694.	2.5	22
33	Phenotypic and Functional Characteristics of Blood Natural Killer Cells from Melanoma Patients at Different Clinical Stages. PLoS ONE, 2013, 8, e76928.	2.5	58
34	NK cells sense tumors, course of disease and treatments. Oncolmmunology, 2012, 1, 38-47.	4.6	37
35	Interleukin-15 Plays a Central Role in Human Kidney Physiology and Cancer through the $\hat{l}^3$ c Signaling Pathway. PLoS ONE, 2012, 7, e31624.	2.5	26
36	Serum Soluble HLA-E in Melanoma: A New Potential Immune-Related Marker in Cancer. PLoS ONE, 2011, 6, e21118.	2.5	51

#	Article	IF	CITATIONS
37	Interleukin-15 is a major regulator of the cell-microenvironment interactions in human renal cancer. Bulletin Du Cancer, 2011, 98, E32-E39.	1.6	4
38	Mutations of the von Hippelâ€"Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma. Oncogene, 2011, 30, 2622-2632.	5.9	26
39	Unique Functional Status of Natural Killer Cells in Metastatic Stage IV Melanoma Patients and Its Modulation by Chemotherapy. Clinical Cancer Research, 2011, 17, 2628-2637.	7.0	52
40	Dacarbazine Promotes Stromal Remodeling and Lymphocyte Infiltration in Cutaneous Melanoma Lesions. Journal of Investigative Dermatology, 2011, 131, 1896-1905.	0.7	33
41	Cytokeratin 18 expression pattern correlates with renal cell carcinoma progression: Relationship with Snail. International Journal of Oncology, 2010, 36, 1145-54.	3.3	16
42	Early evaluation of natural killer activity in post-transplant acute myeloid leukemia patients. Bone Marrow Transplantation, 2010, 45, 862-871.	2.4	19
43	Human Renal Cancer Cells Express a Novel Membrane-Bound Interleukin-15 that Induces, in Response to the Soluble Interleukin-15 Receptor $\hat{l}_{\pm}$ Chain, Epithelial-to-Mesenchymal Transition. Cancer Research, 2009, 69, 1561-1569.	0.9	53
44	Activation of cytotoxic T-cell receptor ÂÂ T lymphocytes in response to specific stimulation in myelodysplastic syndromes. Haematologica, 2008, 93, 381-389.	3.5	36
45	Two opposite signaling outputs are driven by the KIR2DL1 receptor in human CD4+ T cells. Blood, 2008, 112, 2381-2389.	1.4	19
46	Dendritic cell and natural killer cell cross-talk: a pivotal role of CX3CL1 in NK cytoskeleton organization and activation. Blood, 2008, 112, 4420-4424.	1.4	58
47	Chemokine Receptors Expression and Migration Potential of Tumor-infiltrating and Peripheral-expanded Vl̂39Vl̂2 T Cells From Renal Cell Carcinoma Patients. Journal of Immunotherapy, 2008, 31, 313-323.	2.4	44
48	Generation of a Novel Regulatory NK Cell Subset from Peripheral Blood CD34+ Progenitors Promoted by Membrane-Bound IL-15. PLoS ONE, 2008, 3, e2241.	2.5	42
49	Human CD5 Protects Circulating Tumor Antigen-Specific CTL from Tumor-Mediated Activation-Induced Cell Death. Journal of Immunology, 2007, 178, 6821-6827.	0.8	41
50	Membrane-Bound Interleukin (IL)-15 on Renal Tumor Cells Rescues Natural Killer Cells from IL-2 Starvation-Induced Apoptosis. Cancer Research, 2007, 67, 5594-5599.	0.9	18
51	The HOXB4 homeoprotein improves ex vivo generation of functional human NK-cell progenitors. Leukemia, 2007, 21, 1836-1839.	7.2	8
52	Defects of immune surveillance offer new insights into the pathophysiology and therapy of myelodysplastic syndromes. Leukemia, 2007, 21, 2237-2239.	7.2	7
53	Electrocardiographic features of Korean carbon disulfide poisoned subjects after discontinuation of exposure. International Archives of Occupational and Environmental Health, 2007, 80, 547-551.	2.3	2
54	Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. Leukemia, 2006, 20, 463-470.	7.2	108

#	Article	IF	CITATIONS
55	The Decreased Susceptibility of Bcr/Abl Targets to NK Cell-Mediated Lysis in Response to Imatinib Mesylate Involves Modulation of NKG2D Ligands, GM1 Expression, and Synapse Formation. Journal of Immunology, 2006, 176, 864-872.	0.8	38
56	Chronic myeloid leukemia and allogeneic natural killer cells: a surprising dialogue. Expert Review of Clinical Immunology, 2006, 2, 627-637.	3.0	0
57	Membrane-bound and soluble IL-15/IL-15 $\hat{R}$ 1± complexes display differential signaling and functions on human hematopoietic progenitors. Blood, 2005, 106, 2302-2310.	1.4	69
58	Phosphostim-Activated $\hat{I}^3\hat{I}$ T Cells Kill Autologous Metastatic Renal Cell Carcinoma. Journal of Immunology, 2005, 174, 1338-1347.	0.8	172
59	Human NK Cells Lyse Organ-Specific Endothelial Cells: Analysis of Adhesion and Cytotoxic Mechanisms. Journal of Immunology, 2005, 174, 5573-5582.	0.8	31
60	Altered IFNγ Signaling and Preserved Susceptibility to Activated Natural Killer Cell–Mediated Lysis of BCR/ABL Targets. Cancer Research, 2005, 65, 2914-2920.	0.9	8
61	BCR/ABL Promotes Dendritic Cell–Mediated Natural Killer Cell Activation. Cancer Research, 2005, 65, 6409-6417.	0.9	38
62	Analysis of the natural killer mediated immune response in metastatic renal cell carcinoma patients. International Journal of Cancer, 2004, 109, 393-401.	5.1	29
63	NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood, 2004, 104, 3267-3275.	1.4	291
64	Detection of a Functional Hybrid Receptor $\hat{I}^3$ c/GM-CSFR $\hat{I}^2$ in Human Hematopoietic CD34+ Cells. Journal of Experimental Medicine, 2003, 197, 763-775.	8.5	19
65	Differential STAT3, STAT5, and NF-κB activation in human hematopoietic progenitors by endogenous interleukin-15: implications in the expression of functional molecules. Blood, 2003, 102, 109-117.	1.4	49
66	CD158 receptor controls cytotoxic T-lymphocyte susceptibility to tumor-mediated activation-induced cell death by interfering with Fas signaling. Cancer Research, 2003, 63, 7475-82.	0.9	31
67	Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression. Blood, 2002, 99, 2107-2113.	1.4	46
68	Engagement of the inhibitory receptor CD158a interrupts TCR signaling, preventing dynamic membrane reorganization in CTL/tumor cell interaction. Blood, 2002, 100, 2874-2881.	1.4	49
69	Tumor escape from killing: Role of killer inhibitory receptors and acquisition of tumor resistance to cell death. Tissue Antigens, 2002, 60, 273-281.	1.0	30
70	Altered natural killer cell differentiation in CD34+ progenitors from Chronic Myeloid Leukemia patients. Oncogene, 2000, 19, 2758-2766.	5.9	23
71	Killer inhibitory receptor (CD158b) modulates the lytic activity of tumor-specific T lymphocytes infiltrating renal cell carcinomas. Blood, 2000, 95, 2883-2889.	1.4	66
72	NK cells differentiated from bone marrow, cord blood and peripheral blood stem cells exhibit similar phenotype and functions. European Journal of Immunology, 1998, 28, 1991-2002.	2.9	82

#	Article	IF	CITATIONS
73	Les cytokines: outils et cibles privilégiés dans l'immuno-surveillance du cancer. Annales De L'Institut Pasteur / Actualités, 1998, 9, 121-130.	0.1	O
74	TCR analysis reveals significant repertoire selection during in vitro lymphocyte culture. International Immunology, 1997, 9, 1073-1083.	4.0	41
75	Cloning of human IL-12 p40 and p35 DNA into the Semliki Forest virus vector: expression of IL-12 in human tumor cells. Gene Therapy, 1997, 4, 367-374.	4.5	32
76	The hostâ€"tumor immune conflict: from immunosuppression to resistance and destruction. Trends in Immunology, 1997, 18, 493-497.	7.5	327
77	QUANTITATIVE ANALYSIS OF T HELPER 1, T HELPER 2, AND INFLAMMATORY CYTOKINE EXPRESSION IN PATIENTS AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION. Transplantation, 1997, 63, 1307-1313.	1.0	33
78	Inhibition of the human allogeneic mixed lymphocyte response by cyclosporin A: relationship with the ILâ€12 pathway. Tissue Antigens, 1996, 48, 265-270.	1.0	9
79	The renal cell carcinoma lysis by a specific cytotoxic T cell clone is independent of the Fas/Fas‣ cytotoxic pathway. Tissue Antigens, 1996, 48, 295-300.	1.0	6
80	In situ demonstration of renal-cell-carcinoma-specific T-cell clones., 1996, 66, 564-570.		44
81	Analysis of T-cell-receptor variable gene segment usage in peripheral-blood lymphocytes of advanced cancer patients. International Journal of Cancer, 1993, 54, 60-67.	5.1	7
82	Influence of interleukin-2 administration on the expression of T-cell receptor V gene segments in patients with renal-cell carcinoma. International Journal of Cancer, 1993, 54, 741-747.	5.1	8
83	Detection of a Ha-ras point mutation by polymerase chain reaction-single strand conformation polymorphism analysis in 2-amino-3,4-dimethylimidazo[4,5-f]quinoline-induced mouse forestomach tumors. Cancer Letters, 1992, 62, 115-121.	7.2	24
84	Plasminogen receptors on rat colon carcinoma cells. British Journal of Cancer, 1992, 66, 51-56.	6.4	11
85	Histological reactivity of a monoclonal antibody against rat colon cancer cells on human and rat normal gut and colonic tumours. Virchows Archiv A, Pathological Anatomy and Histopathology, 1992, 420, 233-242.	1.4	2
86	An experimentally validated panel of subfamilyâ€specific oligonucleotide primers (V <sub>α</sub> 1â€w29/V <sub>β</sub> 1â€w29/V <sub>1û€w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction. European Journal of Immunology, 1992, 22, 1261-1269.</sub>	2.9	294
87	Molecular characterization of human T cell receptor α chains including a Vδ1-encoded variable segment. European Journal of Immunology, 1991, 21, 1061-1064.	2.9	22
88	F11C antigen: A membrane marker able to distinguish two regressive and progressive variants from a rat colon adenocarcinoma. International Journal of Cancer, 1990, 46, 633-639.	5.1	11
89	in vitro proliferative responses of spleen lymphocytes from rats bearing progressive or regressive tumors induced by cell variants of a syngeneic colon carcinoma. International Journal of Cancer, 1989, 43, 334-339.	5.1	7
90	Activated K-rasin Tumorigenic and Non-tumorigenic Cell Variants from a Rat Colon Adenocarcinoma, Induced by Dimethylhydrazine. Japanese Journal of Cancer Research, 1988, 79, 244-249.	1.7	7

#	Article	IF	CITATIONS
91	Specificity of the immune response leading to protection or enhancement by regressive and progressive variants of a rat colon carcinoma. International Journal of Cancer, 1988, 42, 883-886.	5.1	34
92	An immunohistological study of cells infiltrating progressive and regressive tumors induced by two variant subpopulations of a rat colon cancer cell line. International Journal of Cancer, 1987, 40, 87-93.	5.1	37
93	Interaction between two cellular subpopulations of a rat colonic carcinoma when inoculated to the syngeneic host. International Journal of Cancer, 1985, 36, 273-279.	5.1	114
94	Role of macrophage in the defense against intestinal cancers. Comparative Immunology, Microbiology and Infectious Diseases, 1985, 8, 147-157.	1.6	7
95	Effects of cimetidine and indomethacin on the growth of dimethylhydrazine-induced or transplanted intestinal cancers in the rat. British Journal of Cancer, 1984, 50, 661-665.	6.4	17
96	Effect of indomethacin on the growth of colon cancer cells in syngeneic rats. International Journal of Immunopharmacology, 1984, 6, 329-334.	1.1	12
97	Cytofluorescence localization of adriamycin in resistant colon cancer cells. Cancer Chemotherapy and Pharmacology, 1984, 13, 14-18.	2.3	38
98	Selection by trypsin of two sublines of rat colon cancer cells forming progressive or regressive tumors. International Journal of Cancer, 1983, 32, 623-627.	5.1	171
99	Enhancement of Amyloidosis by Chenodeoxycholic Acid Ingestion in the Hamster. Digestion, 1982, 24, 264-273.	2.3	1
100	A fear survey schedule for use in behaviour therapy. Behaviour Research and Therapy, 1964, 2, 27-30.	3.1	936